14
Views
2
CrossRef citations to date
0
Altmetric
Research Article

Comparative clinical evaluation of the activity of Ser-316 suppository in the treatment of lumbar osteoarthrosis

Pages 413-422 | Received 13 Mar 1991, Published online: 12 Aug 2008
 

Summary

In a double-blind, randomized study, 47 patients suffering from lumbar osteoarthrosis were treated with either Ser-316 suppository (horse immune serum directed against bone and parathyroidal glands) or placebo over a period of 6 months at a dose of 3 suppositories/week. Efficacy was assessed based on the reduction in severity of pain on motion, consumption of paracetamol tablets, functional disability in normal and professional life; on the improvement of motility as shown by fingers-floor distance, Schober Index, extension, lateral flexions; and on the global evolution of the disease. Statistically significant improvements for fingers-floor distance, lateral flexions, paracetamol consumption, pain on motion, disability in normal life and evolution of the disease were seen in the Ser-316 group compared with the results obtained in placebo-treated patients, and were evident mainly from the third month of treatment. Globally, 17 (74%) of 23 patients receiving Ser-316 were considered by both patients and physician to have shown a good or excellent response compared with only 3 (14%) of 22 patients on placebo. There were no reports of any adverse reactions in either treatment group.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.